Hereditary angioedema

25 trials 6 recruiting MedDRA PT
25 Registered trials
6 Recruiting
9 Unique sponsors
10 Unique IMPs
25 Commercial trials
Drug classes (ATC)
— ATC code not specified 24
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 9 substances
Monoclonal antibody 1 substance
Phase III: 11 Phase II: 4 Phase I/II: 3 Phase III/IV: 1 Phase IV: 1 Phase I: 2 Phase I (Other): 3

Filter these 25 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 25 trials

Phase III

11 trials
  • Adarx Pharmaceuticals Inc. Commercial
    ADX-324
    2025-521352-38-00 11 countries 2026 n=36
    Recruiting
  • Astria Therapeutics Inc. Commercial
    NAVENIBART
    2025-521142-22-00 11 countries 2026 n=53 Orphan
    Recruiting
  • Astria Therapeutics Inc. Commercial
    NAVENIBART
    2025-521660-35-00 11 countries 2025 n=53 Orphan
    Recruiting
  • Biocryst Pharmaceuticals Inc. Commercial
    BEROTRALSTAT
    2024-511257-22-00 6 countries 2022 n=19
    Ended
  • CSL Behring LLC Commercial
    GARADACIMAB
    2022-502386-13-00 2 countries 2024 n=7 Orphan
    Ended
  • CSL Behring LLC Commercial
    GARADACIMAB
    2024-510777-18-00 5 countries 2021 n=52 Orphan
    Ended
  • Intellia Therapeutics Inc. Commercial
    ZICLUMERAN, LONVOGURAN
    2024-515741-42-00 3 countries 2025 n=29 Orphan
    Ended
  • Ionis Pharmaceuticals Inc. Commercial
    DONIDALORSEN
    2023-509201-77-00 8 countries 2022 n=55
    Ended
  • Ionis Pharmaceuticals Inc. Commercial
    DONIDALORSEN
    2025-523499-22-00 3 countries 2026 n=8 Orphan
    Recruiting
  • Pharvaris Netherlands B.V. Commercial
    DEUCRICTIBANT
    2024-516247-62-00 10 countries 2025 n=37
    Ended
  • Pharvaris Netherlands B.V. Commercial
    DEUCRICTIBANT
    2024-516248-24-00 11 countries 2025 n=78
    Recruiting

Phase II

4 trials
  • Astria Therapeutics Inc. Commercial
    NAVENIBART
    2023-506540-16-01 4 countries 2025 n=26
    Ended
  • Ionis Pharmaceuticals Inc. Commercial
    DONIDALORSEN
    2024-517249-15-00 1 country 2020 n=7
    Ended
  • Pharvaris Netherlands B.V. Commercial
    (S)-N-(1-DEUTERO-1-(3-CHLORO-5-FLUORO-2-((2-METHYL-4-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)QUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-2-(DIFLUOROMETHOXY)ACETAMIDE
    2023-505549-18-00 6 countries 2022 n=21
    Ended
  • Shanghai Argo Biopharmaceutical Co. Ltd. Commercial
    BW-20805
    2024-518207-22-00 4 countries 2025 n=10
    Ended

Phase I/II

3 trials
  • Astria Therapeutics Inc. Commercial
    STAR-0215
    2022-502953-32-01 4 countries 2024 n=25
    Ended
  • Intellia Therapeutics Inc. Commercial
    ZICLUMERAN, LONVOGURAN
    2023-507956-56-00 3 countries 2024 n=19
    Recruiting
  • Intellia Therapeutics Inc. Commercial
    ZICLUMERAN, LONVOGURAN
    2024-512317-40-00 3 countries 2022 n=15
    Ended

Phase III/IV

1 trial
  • Biocryst Pharmaceuticals Inc. Commercial
    BEROTRALSTAT
    2024-511285-37-00 7 countries 2021 n=45
    Ended

Phase IV

1 trial

Phase I

2 trials
  • Regeneron Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-515285-14-00 1 country 2025 n=72
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    IMP not specified
    2024-515286-34-00 1 country 2025 n=56
    Ended

Phase I (Other)

3 trials
  • Pharvaris Netherlands B.V. Commercial
    IMP not specified
    2023-506305-18-01 1 country 2024 n=14
    Ended
  • Pharvaris Netherlands B.V. Commercial
    IMP not specified
    2024-511196-15-00 1 country 2024 n=14
    Ended
  • Pharvaris Netherlands B.V. Commercial
    IMP not specified
    2024-518453-41-00 1 country 2024 n=18
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pharvaris Netherlands B.V. Commercial 6 Phase I (Other), Phase II, Phase III 1
Astria Therapeutics Inc. Commercial 4 Phase II, Phase III, Phase I/II 2
Ionis Pharmaceuticals Inc. Commercial 3 Phase II, Phase III 1
CSL Behring LLC Commercial 3 Phase III, Phase IV 0
Intellia Therapeutics Inc. Commercial 3 Phase III, Phase I/II 1
Regeneron Pharmaceuticals Inc. Commercial 2 Phase I 0
Biocryst Pharmaceuticals Inc. Commercial 2 Phase III/IV, Phase III 0
Shanghai Argo Biopharmaceutical Co. Ltd. Commercial 1 Phase II 0
Adarx Pharmaceuticals Inc. Commercial 1 Phase III 1
New trials by year
2020
1
2021
2
2022
4
2024
6
2025
8
2026
4
← All indication landscapes